PreludeDx™ to Present Data in DCIS and Stage I, II Early Breast Cancer at the 2024 Miami Breast Cancer Conference : vimarsana.com

/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that...

Related Keywords

Cleveland Clinic , Florida , United States , Miami Beach , Michigan , Miami , Franka Vicini , Troy Bremer , Andrew Wade , Chirags Shah , Dan Forche , Cory Dunn , Prelude Corporation Preludedx , Linkedin , National Cancer Institute , Taussig Cancer Institute , University Of California San Francisco , Department Of Radiation Oncology , Facebook , Instagram , Prelude Corporation , Breast Cancer Conference , Novel Biosignature , Early Stage Invasive Breast Cancer , Assess Recurrence Risk , Patients Treated , Chief Scientific Officer , Radiation Therapy Recommendation , Treatment Modality , Ductal Carcinoma , Situ Using , Gene Biosignature , Breast Radiation Oncology , Radiation Oncology , Clinicopathologic Factors Alone , Predicting Radiation Benefit , Breast Conserving Surgery , Gene Biosignature Based , Ipsilateral Breast Recurrence , Radiation Oncologist , Michigan Healthcare Professionals , California San Francisco , Decision Score , Know Your Risk , Fjord Ventures , Preludedx , Health Care Amp Hospitals , Medical Pharmaceuticals , Biotechnology , Conference Call Announcements ,